EUVIMEDEUVIMED entdecken
CrossrefInfokarte

CTLA4 rs3087243-A–linked haplotype is associated with increased CTLA-4 expression and suppressive function in human regulatory T cells

Lucas Nygård, Antti-Pekka Laine, Anna Jartti, Anna-Mari Schroderus, Viola Pitkänen, Laurène Pfajfer, Mikael Knip, Riitta Veijola, Jorma Ilonen, Jorma Toppari, Johanna Lempainen, Tuure Kinnunen

The Journal of Immunology · 2026-10-01 · 215 (10)

DOI: 10.1093/jimmun/vkag276 ↗
AbstractBibliografische Angaben

Abstract

Abstract CTLA-4 is an inhibitory receptor on T cells that limits immune activation by competing with the co-stimulatory receptor CD28 for binding to CD80 and CD86 on antigen-presenting cells. Regulatory T cells (Tregs) employ CTLA-4–mediated transendocytosis as a key suppressive mechanism. Several CTLA4 polymorphisms are associated with autoimmune disease risk and may modulate CTLA-4 expression and function. Here, we analyzed samples from 155 genotyped subjects using flow cytometry and functional assays to determine how haplotypes formed by 3 CTLA4 single-nucleotide polymorphisms shape T-cell phenotype and function ex vivo. The autoimmune-protective CTLA4 rs5742909-rs231775-rs3087243 CAA haplotype was linked to increased intracellular CTLA-4 expression in both Tregs and conventional CD4+ T cells compared with CGG, CAG, and TAG haplotypes, implicating rs3087243 as the likely causal variant. The CAA haplotype was also associated with increased Treg frequencies. In Tregs from CAA/CAA subjects, elevated steady-state CTLA-4 expression promoted enhanced early CTLA-4 surface mobilization following anti-CD3/anti-CD28 stimulation. Moreover, naïve Tregs from CAA/CAA subjects more effectively suppressed naïve CD4+ T-cell proliferation in the presence of CD80/CD86-expressing dendritic cells. Collectively, these findings indicate that the rs3087243-A–linked CAA haplotype is associated with increased CTLA-4 expression and enhanced Treg function, providing a mechanistic explanation for its protective association with autoimmunity.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →